Tag
This article reviews the CHRYSALIS-2 cohort A study demonstrating the potential of combined amivantamab and lazertinib therapy in heavily pretreated EGFR-mutant NSCLC patients.
This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.
This study demonstrates that disitamab vedotin plus toripalimab significantly improves survival outcomes over chemotherapy in untreated HER2-positive advanced urothelial cancer.
This article reviews a phase 2 trial of belzutifan, a HIF-2α inhibitor, demonstrating durable antitumor activity and manageable safety in advanced pheochromocytoma and paraganglioma, highlighting its potential as a targeted therapy.
This review discusses a phase 3 trial demonstrating that sacituzumab govitecan improves progression-free survival in untreated, advanced triple-negative breast cancer patients not eligible for PD-1/PD-L1 inhibitors.
This study uses real-world data to compare the effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib in HER2-positive metastatic breast cancer, confirming their clinical value.
This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.
This retrospective UK study reveals that integrating whole-genome sequencing with clinical and mortality data enhances prognostication and identifies therapeutic targets in breast cancer, particularly in ER-positive, HER2-negative subtypes.
The PECATI phase 2 trial demonstrates that lenvatinib combined with pembrolizumab offers encouraging antitumour activity and a manageable safety profile in platinum-refractory metastatic B3 thymoma and thymic carcinoma, a population with li
Triplet regimens combining hypomethylating agents, venetoclax, and IDH inhibitors demonstrate high remission rates and survival in intensive chemotherapy-ineligible IDH-mutant AML patients, warranting further comparative studies against app
This review synthesizes current evidence on long-term real-world efficacy of adjuvant anti-PD-1 immunotherapy and targeted BRAF/MEK inhibitor therapy in stage III melanoma, highlighting differential recurrence risks, survival benefits, and
Pemigatinib demonstrates high efficacy and manageable toxicity in treating MLN-FGFR1, especially in chronic-phase patients, addressing a critical unmet need in this aggressive neoplasm.
Exosomes, nanoscale vesicles capable of crossing the blood–brain barrier, hold significant potential as targeted therapeutic agents and diagnostic markers in neurodegenerative diseases. Advances in genetic, chemical, and nanomaterial modifi
Lung cancer therapy has evolved from rudimentary surgery and misdiagnosis to a precision medicine era, markedly improving outcomes through targeted therapies and immunotherapy.
A phase 2 trial found that induction targeted therapy with encorafenib and binimetinib before immune checkpoint inhibitors did not improve progression-free survival versus immune checkpoint inhibitors alone in advanced melanoma with BRAFV60
Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.
Combination therapy with encorafenib, cetuximab, and mFOLFOX6 significantly improves progression-free and overall survival compared to standard care in first-line treatment of BRAF V600E–mutated metastatic colorectal cancer.
The EMA’s CHMP recommends Voranigo, a dual IDH1/2 inhibitor, for grade 2 IDH-mutant gliomas, based on phase 3 INDIGO trial results demonstrating significant improvement in progression-free survival and delayed need for further therapy.
